相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Plasma biomarkers of lower gastrointestinal and liver acute GVHD
Andrew C. Harris et al.
BLOOD (2012)
Myeloablative Reduced-Toxicity i.v. Busulfan-Fludarabine and Allogeneic Hematopoietic Stem Cell Transplant for Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome in the Sixth through Eighth Decades of Life
Gheath Alatrash et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2011)
Linearity and Stability of Intravenous Busulfan Pharmacokinetics and the Role of Glutathione in Busulfan Elimination
Shlomo Almog et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2011)
Comparative analysis of BU and CY versus CY and TBI in full intensity unrelated marrow donor transplantation for AML, CML and myelodysplasia
J. P. Uberti et al.
BONE MARROW TRANSPLANTATION (2011)
Long-term complications and side effects after allogeneic hematopoietic stem cell transplantation: an update
B. Mohty et al.
BLOOD CANCER JOURNAL (2011)
Total body irradiation plus cyclophosphamide versus busulphan with cyclophosphamide as conditioning regimen for patients with leukemia undergoing allogeneic stem cell transplantation: a meta-analysis
Xu Shi-Xia et al.
LEUKEMIA & LYMPHOMA (2010)
Busulfan in Hematopoietic Stem Cell Transplantation
Stefan O. Ciurea et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2009)
Reduced-toxicity conditioning therapy with allogeneic stem cell transplantation for acute leukemia
Borje S Andersson et al.
CURRENT OPINION IN ONCOLOGY (2009)
Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission Systematic Review and Meta-analysis of Prospective Clinical Trials
John Koreth et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS
Borje S. Andersson et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2008)
Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia
Richard F. Schlenk et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: Fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine/busulfan
A. Shimoni et al.
LEUKEMIA (2007)
Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?
Jan J. Cornelissen et al.
BLOOD (2007)
Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity
A Shimoni et al.
LEUKEMIA (2006)
Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan plus cyclophosphamide for allogeneic bone marrow transplantation
JH Lee et al.
ANNALS OF HEMATOLOGY (2005)
Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS
M de Lima et al.
BLOOD (2004)
Intravenous busulfan-based conditioning prior to allogeneic hematopoietic stem cell transplantation: Myeloablation with reduced toxicity
A Shimoni et al.
EXPERIMENTAL HEMATOLOGY (2003)
Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulphan-cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission
MR Litzow et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: Decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality
A Kashyap et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2002)
Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: A phase II study
BS Andersson et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2002)
Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia:: long-term follow-up of 4 randomized studies
G Socié et al.
BLOOD (2001)
Pathogenesis of acute graft-versus-host disease: Cytokines and cellular effectors
JLM Ferrara
JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH (2000)
Acute safety and pharmacokinetics of intravenous busulfan when used with oval busulfan and cyclophosphamide as pretransplantation conditioning therapy: A phase I study
BS Andersson et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2000)
分享论文
